Fundraising Events

2026 St. George, Utah Marathon

7:00 am to 7:00 pm MDT
A family smiling at the camera after a Champion's event by the ocean.

The Parkinson's Foundation is an official charity partner for the 2026 St. George Marathon. By signing up to run as a Parkinson's Champion, you commit to raising funds and awareness for the Parkinson's Foundation, and in return you get access to race entry (bib) in addition to to other perks and benefits. 

Click here to visit the team page and register. 

Fundraising Commitment: $750

The St. George Marathon is one of the nation’s top ten races- known for its breathtaking course, flawless organization, and incredible community support. Runners love the smooth downhill route from the Pine Valley Mountains to the red rock canyons of St. George. With ideal weather, a fast course, and an unforgettable finish, this is one race you don’t want to miss.

If you have questions, email SThatcher@Parkinson.org. For more information about the race itself, visit the StGeorgeMarathon.com.

Upcoming Events

Policy & Advocacy

Why State Advocacy Matters and What the Parkinson's Foundation Is Doing About It

🧠 What will you learn in this article?

  • Why state-level policy decisions matter for people living with Parkinson's disease and how you can get involved

  • Ways the Parkinson's Foundation is advancing research funding in California, Florida, Pennsylvania and Minnesota

  • What the Foundation is doing to ban the pesticide paraquat, which has been linked to Parkinson's 

  • How the Foundation is working to expand access to care and insurance coverage for people living with Parkinson's

Press conference with Parkinson's Foundation group

If you’re living with Parkinson’s disease (PD), the decisions being made every day at federal, state and local levels can directly shape your life. States can often move faster than Congress and the federal government to protect and improve the lives of people living with PD. They can experiment, share ideas and build on what neighboring states are doing.

State lawmakers are also a lot more accessible. They live in your communities. And because they represent fewer people, you're more likely to actually get a chance to sit down, share your Parkinson's story and make the case for legislation that can make a difference.

Here's how the Parkinson's Foundation is putting that to work on the state level this year to advance our policy priorities.

Helping to Prevent Parkinson's Disease by Banning Paraquat

Research has linked the widely used herbicide paraquat to an increased risk of developing Parkinson's. Paraquat has been banned in more than 70 countries, but it is still sold and used in the U.S. Even as we push for a nationwide ban, we are also pushing for state-level bans and restrictions in states that are willing to act on the evidence faster than the federal government.

At the start of 2026 state legislative sessions, the Parkinson’s Foundation was tracking bills to ban or restrict paraquat in 13 states. Vermont led the nation with passage of their legislation this year, while several other states are still considering their bills. The Foundation has testified at hearings, organized advocates to reach out to their representatives and showed up at press events.

  • Parkinson's Foundation group with Rep. Steven Malagari

    In Pennsylvania, Parkinson’s Foundation Ambassador Leslie Zimmerman and Research Advocate Chris Kustanbauter met with state lawmakers to share their stories of living with PD and how they were likely exposed to paraquat years before their diagnoses. 

  • In Minnesota, Parkinson’s Foundation Minnesota & Dakotas Chapter Board Member Lisa Erickson testified in support of the paraquat bill in the House and Senate, and spoke at a press conference alongside other advocates. 

  • In New York, Foundation staff and volunteers participated in a paraquat rally on May 13. Research Advocate Mike Mooney spoke about his experience living with Parkinson's and working at a landscaping company in high school and college where he was exposed to chemicals.

Even in states where paraquat legislation has not yet passed, the Foundation made meaningful strides in educating lawmakers and the public about the links between paraquat and Parkinson's disease. That groundwork will drive continued advocacy in 2027 state legislative sessions. 

Funding Parkinson's Research at the State Level

California Advocacy Day group photo

One of the most direct ways states can make a difference is by investing in research. This year, the Parkinson's Foundation is working to secure state research funding in California, Florida, Pennsylvania and Minnesota, with Florida and Pennsylvania building on progress made last year.

In California, the Foundation is championing a bill that would authorize bonds to fund scientific research on Parkinson's disease and several other diseases. On April 13, Associate Vice President of Advocacy and State Policy Deborah Swerdlow joined around 50 Parkinson's advocates from across California, including volunteers and board members of the Parkinson's Foundation California Chapter, at the State Capitol for a Parkinson's Advocacy Day. 

Advocates met with lawmakers to push the bill forward, educate legislators on the dangers of the herbicide paraquat and discuss legislation to improve emergency preparedness and home- and community-based services. If the State Legislature passes this bill, it will appear on the November 2026 ballot for voters to approve the funding.

Improving Access to Care and Coverage

The Parkinson's Foundation is working on two fronts when it comes to care: 

  1. Improving quality of life for people with Parkinson's and their care partners right now

  2. Building toward a future where every person who receives a Parkinson's diagnosis can access timely, affordable, quality care

The Foundation has joined a nationwide coalition — including organizations focused on cancer, arthritis, ALS and Alzheimer's disease — to expand insurance coverage for biomarker testing at the state level. Biomarkers are biological signs that can be measured to help diagnose a disease, track how it's progressing and evaluate whether treatments are working. 

When insurance is required to cover biomarker testing, it becomes more affordable and more accessible. Thanks to this coalition's work, Mississippi and Tennessee enacted biomarker coverage in 2026 and the push continues in other states.

Looking ahead, the Parkinson's Foundation has developed a multiyear roadmap to transform PD care through policy reform and coordinated action. Parkinson's Care and Innovation: A Patient-Centered Agenda for Change outlines four priority solutions to guide policy action, as well as the federal National Parkinson's Project. It grew out of conversations with care leaders, experts, people living with Parkinson's and innovators because people with Parkinson's are at the center of everything we do. Learn more about the roadmap. 

Get Involved

What happens at the state level is connected to everything. The research funding secured this year could become a new treatment option in five years. A paraquat ban passed now could mean fewer diagnoses in your community. Insurance coverage expanded today helps a person with Parkinson's afford their care tomorrow.

Want to get involved? Visit our Advocacy Center to join our Advocacy Network and contact your representatives. You can also directly reach our policy team at Policy@Parkinson.org.

Raise Awareness

Mi Historia con EP – Ian Rodriguez

Ian Rodriguez con guantes de boxeo

Me acuerdo que, a la edad de 10 años, miré los primeros temblores en mi mano derecha y mi marcha al caminar se sentía diferente. También quería entender qué le estaba pasando a mi cuerpo. 

Me diagnosticaron en el 2002, a la temprana edad de 25 años. Ahorita tengo 48. Así es que tengo 23 años luchando contra la Enfermedad de Parkinson (EP).

Llevo viviendo con Parkinson muchos años, pero nunca he dejado de buscar respuestas.

Desde mi diagnóstico, he querido saber más y tener más información acerca del Parkinson. Este soy yo. Encontré la Parkinson’s Foundation porque tiene mucha información y muchos recursos. Desde dar soluciones hasta tener mucha información y siempre disponible en Parkinson.org

Me enteré en la TV de que la Fundación estaba haciendo un estudio genético. Así encontramos PD GENEration: impulsado por la Parkinson’s Foundation en línea y me inscribí para participar. Cuando descubrí que la Fundación estaba realizando este estudio, supe que quería participar. Me sentí motivado a participar sólo porque quería aprender más acerca de mi Parkinson. Participar era una oportunidad de entender mejor mi propia historia.

PD GENEration: Impulsado por la Parkinson’s Foundation, es un estudio genético global que proporciona pruebas genéticas y consejería genética sin costo para las personas con Parkinson.

Mi experiencia con PD GENEration fue muy, muy fácil. nada de problemas. Llené la información de mi nombre y formulario en línea y después, me mandaron el kit a la semana.

Después de recibir mis resultados, la sesión de consejería genética me pareció muy interesante y me dio validez. Siempre pensé que la razón de que yo tuviera la enfermedad de Parkinson era ambiental, porque mis papás fueron agricultores en los años 1970s. Siempre pensé que habíamos estado expuestos a químicos relacionados con la EP. 

Los resultados me sorprendieron. Cuando descubrí que tenía variantes genéticas de la EP, me sorprendí. Nunca imaginé que tenía el gen desde niño. 

Tener respuestas reales ha cambiado mi forma de ver la enfermedad de Parkinson. PD GENEration me abrió una puerta al conocimiento que no tuve antes.

La sorpresa fue que de los siete principales genes relacionados con la EP para los que me testaron, salí positivo en dos. Entonces, básicamente, me explicó el genetista que tengo dos genes del Parkinson y eso me dejó pensando, “¡Wow!”

Me siento bien de saber más información sobre mi Parkinson. Ahora tengo un documento válido que demuestra que yo cargo el gen del Parkinson.

Para quien viva con Parkinson, les recomiendo mucho que participen en PD GENEration. ¿Por qué no saber más acerca de uno mismo? ¿Acerca de su Parkinson? 

Ian Rodriguez de pie junto a una máquina de ejercicios

Creo que este estudio es especialmente valioso para la comunidad de la EP porque en nuestra comunidad hispana, la investigación del Parkinson no siempre nos alcanza ni refleja. Muy a menudo, un diagnóstico es donde termina el recorrido de la EP para muchos. Un doctor te dice que es Parkinson y ya no hacemos nada más. 

Como hispanos, necesitamos participar en estudios como este. Nuestra comunidad merece tener acceso a la información y a oportunidades como PD GENEration. participar en las investigaciones es alzar la voz de los hispanos en la investigación.

PD GENEration fue una buena experiencia para mí. Recibí buenas noticias: las respuestas a las preguntas que quería saber acerca de mi Parkinson. 

Participar en este estudio tuvo un impacto en mi familia. Tengo dos hijas y ahora estoy pensando en su futuro. Participar no fue sólo para mí; fue para mi familia. Siento que participe en las investigaciones así hoy abre las puertas a las generaciones futuras. 

La investigación es esperanza.

Lea la historia de Ian en inglés

Los testimonios proporcionados por los participantes del estudio reflejan experiencias personales y no necesariamente representan las opiniones del patrocinador del estudio. No sustituyen el consejo médico, y los resultados del estudio pueden variar según las circunstancias individuales. Consulte siempre con su proveedor de atención médica antes de tomar cualquier decisión relacionada con su salud.

Al participar en PD GENEration, los participantes pueden descubrir nuevos conocimientos acerca de su genética, entender los riesgos de su familia y ayudar a beneficiar a las futuras generaciones. Aprenda más e inscríbase hoy.

Podcasts

Episode 191: Speaking with Intention

Changes in speech and swallowing are common in Parkinson’s disease (PD), but they can be difficult to recognize without understanding how they may present. These changes often happen because of lower dopamine levels in people with PD, which can make automatic actions- like speaking loud, clear sentences without requiring much thought- more difficult.  

Parkinson Voice Project developed the SPEAK OUT! Therapy Program to help people with PD speak and swallow with intention, addressing these challenges. 

In the episode, we speak with Samantha Elandary, MA, CCC-SLP, President and Chief Executive Officer of Parkinson Voice Project. She discusses the benefits of working with a Certified SPEAK OUT! Provider, how to identify signs of speech and swallowing difficulties, and offers tips for incorporating these techniques into daily life. Toward the end of the episode, Samantha demonstrates a brief speech exercise that takes just a few minutes but can provide meaningful benefits when practiced consistently and intentionally. 

Released: May 12, 2026

Science News

New Molecule Designed to Block the Protein Buildup Behind Parkinson's

🧠 What will you learn in this article?

This article highlights a new study that found a potential way to treat the underlying cause of Parkinson’s disease, not just its symptoms. It discusses how:

  • In the brain, the abnormal clumping and spread of a protein called alpha-synuclein leads is tied to Parkinson’s. Current therapies address PD symptoms, not this process.

  • Researchers developed SK-129, a molecule that can stop these clumps from forming and spreading in various models of Parkinson’s.

  • In different models, SK-129 saved dopamine neurons and improved outcomes — protecting neurons even after damage began and boosting mouse survival while preventing movement impairment and brain inflammation.

Parkinson's Foundation Science News blogs

In Parkinson’s disease (PD), a protein called alpha-synuclein misfolds and clumps together inside brain cells. These clumps are thought to damage neurons over time and can spread from cell to cell, driving the disease forward. Currently, treatments for PD only manage symptoms — none can slow or stop this underlying process.

Scientists are working hard to find disease-modifying therapies for Parkinson’s. A new study published in Science Translational Medicine may offer a path forward. Researchers at the University of Denver and NYU Abu Dhabi — co-led by Sunil Kumar, PhD, a Parkinson's Foundation Stanley Fahn Junior Faculty Awardee — have developed a special molecule called SK-129 that shows promise in blocking alpha-synuclein from clumping and spreading in the brain. The Parkinson’s Foundation directly funded this work.

Think of alpha-synuclein clumping like a chain reaction: one misfolded protein causes the next one to misfold, and so on, eventually building up harmful deposits. SK-129 is designed to interrupt that chain reaction before it gets started.

Because the SK-129 molecule interacts with important regions of alpha-synuclein, it can latch onto the misfolded protein and prevent it from recruiting others into clumps. Importantly, it targets the toxic, clumped forms of the protein rather than the healthy form, which has normal functions in the brain.

What is SK-129 and how does it impact Parkinson’s?

In Parkinson's, a protein called alpha-synuclein clumps inside brain cells.

                                                                 ➡️

These clumps are thought to damage neurons and spread, making PD symptoms worse over time.

                                                                 ➡️

Researchers developed a molecule called SK-129 that can stop these clumps from forming and spreading — stopping a chain reaction before it starts.

“Our study is unique in that it targets the most toxic forms of α-synuclein — oligomers — offering a new way to significantly slow disease symptoms. This approach creates hope for disease-modifying therapies not only for Parkinson’s, but also for related disorders like Lewy body dementia. That gives us real hope that disease-modifying therapies for Parkinson’s are within reach.”

- Dr. Kumar, study lead and Parkinson’s Foundation research grantee

Key advantages of SK-129 are its size and shape. Other strategies to block alpha-synuclein clumping, such as antibodies, are large molecules that struggle to cross the blood-brain barrier (the protective layer between the bloodstream and the brain). SK-129 is small and compact enough to cross this barrier. Additionally, once in the brain, the molecule was able to stay there for multiple days, which is essential for sustained treatment.

Study Results

The research team tested SK-129 across a remarkably wide range of models — from human cells and patient-derived tissue to worm and mouse models of PD.

In worm models of PD, untreated worms lost most of their dopamine-producing neurons over time. Worms treated preventatively with SK-129 retained nearly all of them, along with restored movement and behavior. Critically, SK-129 may be more than a preventive measure. When given after disease had already set in — after about 30% of dopamine neurons had already been lost — it still rescued a significant number of remaining neurons. This is important because people with Parkinson’s are typically diagnosed after symptoms have already appeared.

In a mouse model of PD, untreated mice survived an average of about 175 days, with fewer than 20% surviving to 270 days. Those that survived showed severe movement problems. In contrast, mice treated with SK-129 had 100% survival to 270 days and showed no signs of movement impairment. Brain tissue from treated mice showed no harmful protein deposits or signs of brain inflammation.

To test the molecule in human samples, the researchers tested SK-129 using exosomes — tiny cellular packages — isolated from the blood of people with Parkinson’s. These exosomes carried misfolded alpha-synuclein that could trigger clumping in cells grown in a petri dish. Adding SK-129 blocked this process.

Another interesting finding was that SK-129 also blocked alpha-synuclein from clumping together with tau, a protein linked to Alzheimer’s disease. Tau is increasingly recognized as being important in Parkinson’s too; about half of people with PD also have tau-related brain changes, which can worsen both movement and cognitive symptoms. In the mouse model, treated mice showed no evidence of combined alpha-synuclein and tau deposits, while untreated mice did. In short, while SK-129 is designed to target harmful alpha-synuclein deposits, it also prevented alpha-synuclein from clumping with tau as well.

Highlights

  • Researchers developed a molecule, called SK-129, that can make it to the brain and attach to toxic forms of the protein associated with Parkinson’s called alpha-synuclein.

  • SK-129 latches onto the hallmark PD protein and prevents it from launching a clumping chain reaction.

  • In multiple models of PD (including cells, worms, mice and human-derived tissue), treatment with SK-129 prevented alpha-synuclein clumping and rescued signs of neurodegeneration.

  • SK-129 shows promising therapeutic properties, including the ability to effectively reach the brain, preferentially bind to toxic forms of alpha-synuclein, and remain in brain tissue for a prolonged period of time.

What Does This Mean?

While early, SK-129 has the potential to be a breakthrough Parkinson’s treatment. This study represents an important step toward a long-sought goal: a disease-modifying treatment that addresses the underlying cause of Parkinson’s disease instead of only symptoms.

This research supports a promising strategy at the forefront of Parkinson’s research: targeting the clumping and spread of alpha-synuclein, a suspected driver of PD progression. Earlier approaches have struggled because they were not specific enough, couldn’t enter the brain or didn’t last long enough in the brain to be effective.

Importantly, SK-129’s unique features have overcome many of these challenges, making it a promising potential therapy. Despite this progress, SK-129 still needs thorough safety testing and studies in more complex models before clinical trials can begin, so it will likely be years before it is available. This is why funding a diverse range of Parkinson’s research studies is so important.

What Do These Findings Mean for People with Parkinson’s Right Now?

SK-129 is not yet a treatment available to people. It is still in the preclinical stage, with next steps already underway.

“Next, we’ll move SK-129 toward clinical development by testing its safety and dosing,” said Dr. Kumar. “A key priority is to establish a clear link between dose, effectively targeting the harmful alpha-synuclein and producing real benefits in animal models. At the same time, we are optimizing related molecules to improve strength, access to the brain and stability, to help identify the best candidate for future clinical trials.” 

For people with Parkinson’s, continue current care — medications, exercise, therapy) — and consider clinical trials if interested. While SK-129 is likely years away from human testing, the development of molecules like this represents meaningful progress and demonstrates the importance of supporting preclinical Parkinson’s research.

Learn More

The Parkinson’s Foundation believes in empowering the Parkinson’s community through education. Learn more about PD treatments and ongoing research through our resources below, or by calling our free Helpline at 1-800-4PD-INFO (1-800-473-4636) for answers to your Parkinson’s questions.

Educational Events

28TH Annual Vanderbilt Parkinson's Educational Symposium

10:00 am to 2:00 pm CDT
FREE
Ochsner’s 18th Annual Parkinson's Disease Symposium

Please join the Vanderbilt Medical Center and Parkinson’s Foundation Center of Excellence team for the 28th Annual Vanderbilt Parkinson’s Educational Symposium.

There is no charge to attend, but registration is required. This program is open to people with Parkinson's, their family, friends, and the community.

Upcoming Events

Educational Events

Parkinson's Foundation Florida Chapter Community Conversation

9:30 am to 1:00 pm EST
FREE
Person raising hand

This program offers an introduction and basic overview of Parkinson’s disease (PD). PD varies from person to person and changes over time. Discover its causes, common symptoms and available treatments. Learn practical daily living tips to empower you to take charge of your health and to navigate the challenges of living with PD.

There is no charge to attend, but registration is required. This event is open to people with Parkinson's, their family, friends and the community.

Upcoming Events

Advancing Research

Inside the Science: Parkinson's Research Today

🧠 What will you learn in this article?

This article highlights three key Parkinson’s research areas scientists are exploring right now. It discusses:

  • How Parkinson’s research is accelerating because there’s no cure, cases are rising globally and the U.S. economic burden is significant.

  • Three especially active research targets are alpha-synuclein protein aggregation, mitochondrial dysfunction and brain inflammation — and how they interact.

  • New tools are underway to help with earlier and more precise detection, better tracking of progression and moving toward personalized, disease-modifying treatments.

Team of scientists in a lab

Parkinson’s disease (PD) research is advancing rapidly, with breakthroughs on the horizon that could transform treatment and offer hope to millions.

Three key research areas are among the most active and promising: alpha-synuclein aggregation, mitochondrial dysfunction and neuroinflammation. Learn what these terms mean, where the science is headed and how advances in these areas may lead to new treatments and disease-modifying therapies.

This article is based on a Parkinson’s Foundation Expert Briefingexploring advances in Parkinson’s research hosted by Laurie Sanders, PhD, Associate Professor, Neurology and Pathology, Movement Disorders and Translational Brain Sciences divisions, at Duke University School of Medicine, a Parkinson's Foundation Center of Excellence.

Urgency is Driving Research

The pressing need to crack the code behind the causes of Parkinson’s has never been greater. Though there are a wide variety of treatments to manage PD symptoms, there is no cure. More than 11 million people worldwide are living with Parkinson’s, including more than 1 million in the U.S.

PD cases are expected to exceed 25 million globally by 2050. The economic impact is staggering: Parkinson's cost the U.S. $82.2 billion in 2024. More than $23 billion went toward direct medical costs, while nearly $60 billion reflects indirect costs, including lost income and burdens on care partners.

The determination to solve the Parkinson’s mystery is possibly best reflected in the number of current studies in the research pipeline. The National Institutes of Health’s (NIH) ClinicalTrials.gov shows more than 200 Parkinson’s-related clinical trials either actively recruiting or about to recruit. In addition, foundational research that advances our overall understanding of Parkinson’s biology continues to take place, especially in the following areas.

3 Key Parkinson’s Research Areas Right Now

Parkinson’s is complex, as scientists believe a combination of environmental and genetic factors are the cause of Parkinson's. Research requires attacking the problem from multiple angles. Studies suggest the development and progression of Parkinson’s involves interactions among three key biological areas:

1. Protein Aggregation: Alpha-synuclein

Parkinson’s involves the loss of dopamine-producing neurons and a buildup of alpha-synuclein, a normally useful protein found in the brain that helps brain cells communicate. There is very strong genetic evidence linking alpha-synuclein to Parkinson’s disease via the SNCA gene, which was the first PD-associated gene to be identified.

Alpha-synuclein becomes problematic when it misfolds, gathering into clumps called Lewy bodies that can spread between brain cells. Many PD treatments target and remove these alpha-synuclein clumps. However, while Lewy bodies are a hallmark of Parkinson’s, there is still some controversy over whether they are part of the Parkinson’s problem or act as a protective factor.

2. Mitochondrial Dysfunction

Mitochondria are energy powerhouses that are critically important to good health. They malfunction in Parkinson’s, impacting cellular energy and contributing to cell death. Neurons — brain cells that send electrical and chemical communications — are especially vulnerable to mitochondrial dysfunction.

Certain gene mutations can impact mitochondrial function, as can environmental toxins like pesticides (such as paraquat).

Genetic risk factors, including PINK1 and PRKN that are specifically related to mitochondria, can also influence PD development and severity.

3. Brain Inflammation

When combined with the other two factors, studies suggest that brain inflammation (the brain’s protective response to harm, which may become overstimulated in Parkinson’s) can make those problems worse. In addition, inflammation can weaken the blood-brain barrier that may allow immune cells from the blood to enter the brain, which can accelerate neurodegeneration.

Advances Accelerating Parkinson’s Research

Once considered solely a movement disorder, we now know Parkinson’s is a multisystem disease that can affect the whole body — including urinary problems, gut issues and changes to thinking, sleep and mood.

Patient engagement is essential for PD research progress. Major influences that deepen our understanding of PD risk include studies with global reach like PD GENEration: Powered by the Parkinson’s Foundation, which is providing insights as to how Parkinson’s is tied to genetics through providing genetic testing and counseling to people with a confirmed PD diagnosis. Importantly, the biological discoveries made about Parkinson’s via genetic testing may also apply to Parkinson’s cases that do not have a known genetic link.

New tools are being developed that hold the possibility to detect Parkinson’s earlier, better understand its progression and help track the effectiveness of PD therapies. These tools include:

  • Brain imaging to help researchers visualize the spread of Parkinson’s, identify specific areas of brain pathology and increase diagnosis accuracy including advances in developing positron emission tomography (PET) ligands, high-resolution MRI and diffusion imaging.

  • Ultrasensitive lab tests to measure new Parkinson’s biomarkers from spinal fluid and other fluids such as blood. These tests include:

    • alpha-synuclein seeding assays (SAAs) to detect tiny amounts of misfolded alpha-synuclein.

    • tests that can identify neurodegeneration, such as for the protein neurofilament light, which has been linked to PD, and other markers of inflammation.

    • Tests for mitochondrial DNA damage, such as MitoDNADX, a recent blood test developed by Duke University researchers for use as a potential biomarker in PD.

  • Improved disease models, including:

    • induced pluripotent stem cells (iPSCs), developed by recoding cells from people with PD to become dopamine neurons, allowing for the study of PD-related cell dysfunction in patient tissue. 

    • organoids, which are miniature brains that allow scientists to study Parkinson’s mechanisms and test possible therapies.

    • refined animal models, that are genetically engineered to better model Parkinson’s symptoms.

Research Breakthroughs and Targets

Scientists are investigating ways to slow or halt Parkinson’s, identify people for participation in relevant PD trials and deliver targeted treatments.

Nearly 100 forms of alpha-synuclein have been identified, with research to determine which are most toxic. As scientists dig deeper into PD progression, they have also discovered alpha-synuclein pathology along the GI tract of people with PD.

Parkinson’s and GI research is expanding, including through the Gut-Brain Communication in Parkinson’s Disease Consortium, a joint effort between the NIH and the Duke Clinical Research Institute.

Many people with Parkinson’s also experience the buildup of other proteins such as Beta-amyloid plaques and Tau tangles, key hallmarks of Alzheimer’s disease. One promising study under way is exploring whether oral therapy buntanetap is safe for long-term use in people with PD. Buntanetap aims to reduce other toxic proteins. Investigational Parkinson’s treatments also include immunotherapies that use antibodies to target harmful protein clumps and approaches that help cells manage or remove misfolded proteins.

Mutations in the GBA1 gene, a common genetic risk factor for Parkinson’s, reduce the activity of the glucocerebrosidase enzyme, contributing to alpha-synuclein buildup. New treatments are being developed to boost glucocerebrosidase activity to help cells more effectively remove harmful buildup. A variety of therapies are also in the research pipeline to rescue mitochondrial function.

The Way Forward

Parkinson’s research is fundamental for progress toward new disease-modifying therapies that can slow or stop disease progression. By improving our understanding of the ways in which alpha-synuclein, mitochondrial dysfunction and inflammation interact, we get closer to having personalized, precision-medicine treatments for PD. When we combine this knowledge with patient participation in research, breakthroughs in technology and new biomarker discoveries, we continue to advance closer to a cure for Parkinson’s.

How to get involved:

Advancing Research

Meet the Researcher Working to Develop an Imaging Biomarker for Parkinson’s

🧠 What will you learn in this article?

This article highlights a researcher working to develop a biomarker tag called a PET tracer for Parkinson’s disease (PD). It discusses: 

  • What a PET tracer is and how it could track misfolded alpha-synuclein clumps.

  • How a PET tracer could track disease progression and test therapies.

  • How support from the Parkinson’s Foundation makes research like this possible.

Sarah Shahmoradian headshot

Tracking Parkinson’s disease (PD) progression is challenging, and doctors currently rely on how a person’s symptoms change over time. This method is difficult because symptoms vary from person to person and can fluctuate, making it hard to evaluate if treatments are helping.

For other brain diseases like Alzheimer’s, scientists have developed small molecules that can attach to disease-related protein clumps and make them visible on brain scans such as PET (positron emission tomography). These imaging tools allow researchers and clinicians to see where harmful proteins are building up in the brain, providing a clearer way to track disease progression and test therapies. In short, these imaging tools can act as a biomarker for the disease.

What is a biomarker?

Biomarkers are biological signs that can be measured to help diagnose a disease, track its progression and evaluate if treatments are working.

Sarah Shahmoradian, PhD, recipient of a Parkinson’s Foundation Impact Award, is exploring whether a similar biomarker tag could work for Parkinson’s. Working with collaborators at Massachusetts General Hospital, a Parkinson’s Foundation Center of Excellence, Dr. Shahmoradian is studying a specially designed small molecule that appears to bind to toxic forms of the protein connected to Parkinson’s (called alpha-synuclein). 

“Currently, we do not have a PET tracer that reliably marks clusters of the protein alpha-synuclein when it goes bad, so we can’t tell when these clusters are starting to grow or when they are starting to spread in the brain,” said Dr. Shahmoradian.

Having a Parkinson’s-specific PET tracer to track the alpha-synuclein protein would help PD doctors and care teams:

  • Detect Parkinson’s earlier

  • Monitor how PD spreads over time

  • Evaluate if experimental therapeutics are reducing the clustering and accumulation over time

  • Distinguish Parkinson’s from other conditions with overlapping symptoms

From her lab at the University of Texas Southwestern Medical Center in Dallas, Dr. Shahmoradian will use high-resolution imaging methods — developed through her earlier research, which was supported by a Parkinson’s Foundation Stanley Fahn Junior Faculty Award in 2022 — to see precisely how this new molecule attaches to alpha-synuclein. Understanding this interaction at the molecular level will help scientists fine-tune the tracer for future clinical imaging.

The next step is to adapt the molecule so it glows under the microscope. By applying it to neurons grown in the lab that model Parkinson’s disease, or to slices of PD brain tissue, Dr. Shahmoradian and her team hope to track where alpha-synuclein clumps appear and how they move inside cells.

If successful, this work will demonstrate that the molecule can serve as a powerful diagnostic and research tool for Parkinson’s.

“There is real momentum in Parkinson’s disease research right now. We understand more about the problematic protein alpha-synuclein now than we did a decade ago. Cell models are becoming increasingly sophisticated and there are newer imaging agents and disease-modifying therapies on the horizon.” - Dr. Shahmoradian

Dr. Shahmoradian believes her work brings hope to the Parkinson’s community because through it, researchers like herself can look at problematic alpha-synuclein clumps at extremely high resolution to figure out exactly where the protein goes wrong.

She is grateful for the community she has found through the Parkinson’s Foundation, and the connections she has made with other researchers who are also focused on finding a cure for Parkinson’s disease.

“This research would not be possible without the Foundation’s support, and the donors who made these grants a reality. Your investment is not abstract. You are helping support experiments right now, in real time, that help diagnose and treat Parkinson’s disease. You are accelerating and empowering scientists like myself toward the shared common cause of curing Parkinson’s disease,” said Dr. Shahmoradian.

Meet more Parkinson’s researchers! Explore our My PD Stories featuring PD researchers.

Videos & Webinars

Latest Advances in Parkinson’s Treatments: What Veterans Need to Know

April 23, 2026

The landscape of Parkinson’s treatment is constantly evolving, with exciting advances in medications, therapies, and technologies aimed at improving quality of life and symptom management. In this webinar, we’ll explore the latest evidence-based treatments available to veterans living with Parkinson’s, including emerging therapies and clinical trial opportunities. Learn how to access treatments through the VA system and understand which options may be right for you or your loved one. This session is designed to empower veterans and care partners with up-to-date knowledge and tools for informed decision-making.

Download Slides

Additional Resources

Presenters

Dr. Pavan Vaswani 
Associate Program Director, Movement Disorders Fellowship, Department of neurology, University of Pennsylvania
Attending Neurologist, Corporal Michael J. Crescenz Philadelphia VA Medical Center, University of Pennsylvania 

Dr. George Kannarkat
Assistant Professor of Neurology, Hospital of the University of Pennsylvania
Neurology Consultant, Penn Neurology, Grandview Hospital, Sellersville, PA

Back to Top